In the claims:

- 1. (withdrawn) A host cell being co-transformed with:
- (a) a first expression construct including a first polynucleotide encoding a functional mammalian β -2 microglobulin, being translationally fused upstream of a second polynucleotide encoding a functional MHC class I heavy chain; and
- (b) a second expression construct including a third polynucleotide encoding an antigenic peptide, wherein when said first, second and third polynucleotides are co-expressed in the host cell, an MHC class I-antigenic peptide complex is formed.
- 2. (withdrawn) The host cell of claim 1, wherein said first expression construct further includes an in-frame linker polynucleotide sequence encoding a linker peptide interposed between said first and said second polynucleotides.
- 3. (withdrawn) The host cell of claim 1, wherein said cell is a eukaryotic cell.
- 4. (withdrawn) The host cell of claim 1, wherein said cell is a bacterial cell.
- 5. (currently amended) A method of producing a functional <u>and stable</u> MHC class <u>I-antigenic peptide complex molecule</u> <u>at physiological conditions</u> comprising the steps of:
- (a) expressing, in bacteria, a single chain MHC class I polypeptide including a functional mammalian β -2 microglobulin amino acid sequence covalently linked to a functional mammalian MHC class I heavy chain amino acid sequence; and
 - (b) isolating said single chain MHC class I polypeptide; and

(c) refolding said single chain MHC class I polypeptide in presence of an antigenic peptide capable of binding said single chain MHC class I polypeptide, to thereby generate the functional and stable MHC class I-antigenic peptide complex at physiological conditions.

6. (cancelled)

- 7. (original) The method of claim 5, further comprising the step of:
- (d) isolating said MHC class I-antigenic peptide complex via size exclusion chromatography.
- 8. (original) The method of claim 5, wherein said antigenic peptide is coexpressed along with said single chain MHC class I polypeptide in said bacteria.
- 9. (original) The method of claim 5, wherein step (a) is effected such that said single chain MHC class I polypeptide forms inclusion bodies in said bacteria.
- 10. (original) The method of claim 8, wherein said antigenic peptide and said single chain MHC class I polypeptide form inclusion bodies in said bacteria.
- 11. (original) The method of claim 9, wherein said step of isolating said polypeptide further includes the steps of:
- (i) denaturing said inclusion bodies so as to release protein molecules therefrom; and
 - (ii) renaturing said protein molecules.
- 12. (original) The method of claim 11, wherein said step of renaturing said protein molecules is effected in the presence of an antigenic peptide capable of binding said single chain MHC class I polypeptide.
- 13. (original) The method of claim 12, wherein said antigenic peptide is co-expressed along with said single chain MHC class I polypeptide in said bacteria.

- 14. (original) The method of claim 5, wherein said mammalian β -2 microglobulin amino acid sequence is a human β -2 microglobulin amino acid sequence and further wherein said mammalian MHC class I heavy chain amino acid sequence is a human MHC class I heavy chain amino acid sequence.
- 15. (new) The method of claim 5, wherein said physiological conditions include a temperature in the range of 35-40 °C.